Finerenone plus SGLT2 inhibitor reduces albuminuria more than either drug alone

Key takeaways:

Concurrent use of finerenone and empagliflozin reduced urine albumin-to-creatinine ratio for adults with CKD and type 2 diabetes.

Albuminuria reduction was greater than for either agent used separately.

Adults with chronic kidney disease and type 2 diabetes had slower kidney function decline with a combination of the and empagliflozin than with either drug alone, according to study data.

In addition, researchers observed no clinically significant increased risks for adverse events with the combination therapy. Data the CONFIDENCE trial were presented at the ERA Congress in Vienna and simultaneously published in he New England Journal of Medicine .

“Simultaneous and an SGLT2 inhibitor provides early and additive effects on urine albumin-to-creatinine ratio reduction